<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712465171</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712465171</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>First Case Report of Familial Hypercholesterolemia in an Omani Family Due to Novel Mutation in the Low-Density Lipoprotein Receptor Gene</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Al-Hinai</surname>
<given-names>Ali T.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712465171">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Abri</surname>
<given-names>Abdulrahim</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff2-0003319712465171">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Dhuhli</surname>
<given-names>Humoud</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319712465171">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Waili</surname>
<given-names>Khalid</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0003319712465171">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Sabti</surname>
<given-names>Hilal</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0003319712465171">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Yaarubi</surname>
<given-names>Saif</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff6-0003319712465171">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Hashmi</surname>
<given-names>Khamis</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff7-0003319712465171">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Banerjee</surname>
<given-names>Yajnavalka</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0003319712465171">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Zakwani</surname>
<given-names>Ibrahim</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff8-0003319712465171">8</xref>
<xref ref-type="aff" rid="aff9-0003319712465171">9</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Al-Rasadi</surname>
<given-names>Khalid</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0003319712465171">4</xref>
<xref ref-type="corresp" rid="corresp1-0003319712465171"/>
</contrib>
</contrib-group>
<aff id="aff1-0003319712465171"><label>1</label>Department of Medicine, College of Medicine &amp; Health Sciences, Sultan Qaboos University, Muscat, Oman</aff>
<aff id="aff2-0003319712465171"><label>2</label>Department of Biochemistry, College of Medicine &amp; Health Sciences, Sultan Qaboos University, Muscat, Oman</aff>
<aff id="aff3-0003319712465171"><label>3</label>Department of Radiology, Sultan Qaboos University Hospital, Muscat, Oman</aff>
<aff id="aff4-0003319712465171"><label>4</label>Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman</aff>
<aff id="aff5-0003319712465171"><label>5</label>Department of Surgery, Sultan Qaboos University Hospital, Muscat, Oman</aff>
<aff id="aff6-0003319712465171"><label>6</label>Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman</aff>
<aff id="aff7-0003319712465171"><label>7</label>Department of Clinical Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman</aff>
<aff id="aff8-0003319712465171"><label>8</label>Department of Pharmacology &amp; Clinical Pharmacy, College of Medicine &amp; Health Sciences, Sultan Qaboos University, Muscat, Oman</aff>
<aff id="aff9-0003319712465171"><label>9</label>Gulf Health Research, Muscat, Oman</aff>
<author-notes>
<corresp id="corresp1-0003319712465171">Khalid Al-Rasadi, Department of Clinical Biochemistry, Sultan Qaboos University Hospital, PO Box 38, Al-Khodh, PC-123, Sultanate of Oman. Email: <email>khalid77@squ.edu.om</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>4</issue>
<fpage>287</fpage>
<lpage>292</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder. Mutations have been found in at least 3 genes: the low-density lipoprotein receptor (<italic>LDLR</italic>), apolipoprotein B (<italic>APOB</italic>), and proprotein convertase subtilisin/kexin type 9 (<italic>PCSK9</italic>). We report the first case of FH in an Omani family due to a novel mutation in the <italic>LDLR</italic> gene. A 9-year-old female was referred to our lipid clinic with eye xanthelasmata and thickening of both Achilles tendons. Evaluation of the lipid profile showed the off treatment total cholesterol of 896 mg/dL (23.2 mmol/L), low-density lipoprotein cholesterol (LDL-C) of 853 mg/dL (22.1 mmol/L), APOB of 4.5 g/L, triglyceride of 71 mg/dL (0.8 mmol/L), and high-density lipoprotein cholesterol of 0.74 mmol/L. Genetic analysis of the <italic>LDLR</italic> gene showed a homozygous frameshift deletion mutation (272delG) at exon 3. The female patient was treated with a combination of rosuvastatin/ezetimibe and LDL apheresis.</p>
</abstract>
<kwd-group>
<kwd>familial hypercholesterolemia</kwd>
<kwd>low-density lipoprotein receptor</kwd>
<kwd>xanthoma</kwd>
<kwd>apheresis</kwd>
<kwd>carotid intima media thickness</kwd>
<kwd>mutation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712465171">
<title>Introduction</title>
<p>Familial hypercholesterolemia (FH) is an autosomal dominant disorder resulting in elevated plasma low-density lipoprotein cholesterol (LDL-C). There are 2 forms of FH: heterozygous and homozygous forms. Heterozygous FH (HeFH) is more common, with a reported prevalence of 1/500<sup>
<xref ref-type="bibr" rid="bibr1-0003319712465171">1</xref>
</sup> but the prevalence is higher in some populations such as the Afrikaners in South Africa<sup>
<xref ref-type="bibr" rid="bibr2-0003319712465171">2</xref>
</sup> and French Canadians.<sup>
<xref ref-type="bibr" rid="bibr3-0003319712465171">3</xref>
</sup> The plasma LDL-C in this form ranges between 297 and 425 mg/dL (7.7-11 mmol/L). Homozygous FH (HoFH) is rare, with a prevalence of 1/1 000 000 with plasma LDL-C of 444-1089 mg/dL (11.5-28.2 mmol/L). The FH is characterized by cutaneous as well as tendon xanthomas, arcus cornealis, and generalized atherosclerosis that develop during the childhood. Prior to the introduction of statins, the cumulative risk of fatal and nonfatal coronary heart disease (CHD) reached as high as 50% by the age of 50 years in men and 30% by the age of 60 years in women.<sup>
<xref ref-type="bibr" rid="bibr4-0003319712465171">4</xref>
</sup>
</p>
<p>Most mutations identified are in the low-density lipoprotein receptor (<italic>LDLR</italic>), apolipoprotein B (<italic>APOB</italic>) gene mutation, and proprotein convertase subtilisin/kexin type 9 (<italic>PCSK9</italic>).<sup>
<xref ref-type="bibr" rid="bibr5-0003319712465171">5</xref>
</sup>
</p>
<p>We report a 9-year-old girl with HoFH, a novel mutation in the <italic>LDLR</italic> gene, and premature atherosclerosis.</p>
</sec>
<sec id="section2-0003319712465171">
<title>Case Report</title>
<p>A 9-year-old female, born of a consanguineous marriage, was referred to the lipid clinic with arcus cornealis, xanthelasmata of the eyes, xanthomas of the elbows, tuberous xanthomas, and thickening of both the Achilles tendons (<xref ref-type="fig" rid="fig1-0003319712465171">Figure 1</xref>). Her lipid profile results showed an off treatment total cholesterol (TC) of 896 mg/dL (23.2 mmol/L), LDL-C of 853 mg/dL (22.1 mmol/L), an APOB of 4.5 g/L, triglyceride (TG) of 71 mg/dL (0.8 mmol/L), and high-density lipoprotein cholesterol (HDL-C) of 29 mg/dL (0.74 mmol/L, <xref ref-type="table" rid="table1-0003319712465171">Table 1</xref>). Investigations for secondary causes of hypercholesterolemia were negative. The child was complaining of shortness of breath and atypical chest pains; she had a stress test that was strongly positive for myocardial ischemia. An echocardiography showed mild thickening of the mitral valve with moderate mitral regurgitation and mild left ventricular systolic dysfunction. Carotid intima–media thickness (cIMT) of the common carotid arteries revealed a marked thickness of 1.15 mm on the right and 0.94 mm on the left side of the carotid arteries (<xref ref-type="fig" rid="fig2-0003319712465171">Figure 2</xref>). The coronary calcium score showed no presence of calcification. Achilles tendon ultrasound showed moderate thickening of both the tendons (<xref ref-type="fig" rid="fig3-0003319712465171">Figure 3</xref>).</p>
<fig id="fig1-0003319712465171" position="float">
<label>Figure 1.</label>
<caption>
<p>Photos describe the skin lesions in the patient. Xathelasma of the eyes (A), xanthomas of the elbows (B), tuberous xanthomas of the knees (C), and Achilles tendon thickening with xanthomas (D).</p>
</caption>
<graphic xlink:href="10.1177_0003319712465171-fig1.tif"/>
</fig>
<fig id="fig2-0003319712465171" position="float">
<label>Figure 2.</label>
<caption>
<p>Longitudinal images of the distal right and left common carotid arteries and corresponding transverse images. The Intima–Media thickness is 1.15 mm on the right and 0.94 mm on the left.</p>
</caption>
<graphic xlink:href="10.1177_0003319712465171-fig2.tif"/>
</fig>
<fig id="fig3-0003319712465171" position="float">
<label>Figure 3.</label>
<caption>
<p>Transverse images of the right and left Achilles tendons showing moderate thickening of the tendon bilaterally.</p>
</caption>
<graphic xlink:href="10.1177_0003319712465171-fig3.tif"/>
</fig>
<table-wrap id="table1-0003319712465171" position="float">
<label>Table 1.</label>
<caption>
<p>Baseline Lipid Profile of the Family.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0003319712465171" xlink:href="10.1177_0003319712465171-table1.tif"/>
<table>
<thead>
<tr>
<th>Lipid Fraction</th>
<th>Father</th>
<th>Mother</th>
<th>Patient</th>
<th>Sister</th>
<th>Sister</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC mmol/L</td>
<td>9.0</td>
<td>8.5</td>
<td>32.2</td>
<td>7.4</td>
<td>8.4</td>
</tr>
<tr>
<td>LDL-C mmol/L</td>
<td>7.1</td>
<td>6.4</td>
<td>22.1</td>
<td>5.5</td>
<td>6.7</td>
</tr>
<tr>
<td>HDL-C mmol/L</td>
<td>0.65</td>
<td>1.56</td>
<td>0.74</td>
<td>1.63</td>
<td>1.22</td>
</tr>
<tr>
<td>TG mmol/L</td>
<td>2.8</td>
<td>1.1</td>
<td>0.8</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>ApoB g/L</td>
<td>2.19</td>
<td>1.50</td>
<td>4.5</td>
<td>1.29</td>
<td>1.59</td>
</tr>
<tr>
<td>ApoA1 g/L</td>
<td>0.90</td>
<td>1.26</td>
<td>0.74</td>
<td>1.35</td>
<td>1.24</td>
</tr>
<tr>
<td>Lp(a) mg/L</td>
<td>
</td>
<td>
</td>
<td>1110</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712465171">
<p>Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TGs, triglycerides; ApoB, apolipoprotein B; Apo A, apolipoprotein A; Lp(a), lipoprotein (a).</p>
</fn>
<fn id="table-fn2-0003319712465171">
<p>
<sup>a </sup>To convert mmol/L to mg/dL: for cholesterol divide by 0.0259; for triglycerides divide by 0.0113.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The parents of the patient and 2 of her sisters were also hypercholesterolemic. The off treatment lipid profiles of the family are summarized in <xref ref-type="table" rid="table1-0003319712465171">Table 1</xref>. The father had coronary artery graft (CAG) that showed significant 3-vessel disease; he was scheduled for coronary arterial bypass graft (CABG).</p>
<p>The DNA of the patient and 3 of her family members was analyzed for <italic>LDLR</italic> mutations by direct DNA sequencing. The analysis of the mutations showed a homozygous <italic>LDLR</italic> gene novel frameshift deletion mutation (272delG) at exon 3 in the patient and a similar heterozygous mutation in the father and 2 sisters (<xref ref-type="fig" rid="fig4-0003319712465171">Figure 4</xref>). The mother refused a DNA analysis.</p>
<fig id="fig4-0003319712465171" position="float">
<label>Figure 4.</label>
<caption>
<p>The DNA analysis of the control, patient, and the family, showing the normal sequence in a control, the homozygous frameshift mutation sequence in the patient, and the heterozygous frameshift mutation in the father and the 2 sisters.</p>
</caption>
<graphic xlink:href="10.1177_0003319712465171-fig4.tif"/>
</fig>
<p>The patient was started on a combination of rosuvastatin 10 mg and ezetimibe 10 mg, but these resulted in only a small reduction of the LDL-C to 772 mg/dL (20.0 mmol/L, 9.5% reduction). Direct adsorption of lipoprotein apheresis was commenced and the acute LDL-C post-treatment reduction was 459 mg/dL (11.9 mmol/L, 46% reduction). There were some problems with vascular access that limited the patient from undergoing weekly apheresis; however, despite that the family refused an arteriovenous fistula.</p>
</sec>
<sec id="section3-0003319712465171">
<title>Discussion</title>
<p>The FH is an autosomal dominant disorder that results in high levels of LDL-C and premature atherosclerosis if not diagnosed and treated early.<sup>
<xref ref-type="bibr" rid="bibr6-0003319712465171">6</xref>,<xref ref-type="bibr" rid="bibr7-0003319712465171">7</xref>
</sup> The patient, her father, and her siblings are the first Omani family to undergo genetic analysis for FH mutations, where a novel mutation of the <italic>LDLR</italic> gene was found in the family.</p>
<p>Children with HeFH usually have no symptoms for CHD. In the second decade, 10% to 15% of those affected develop tendon and tuberous xanthomas and xanthelasmata and, if untreated, more than 60% will develop tendon xanthomas by the third decade of life. The LDL-C is elevated approximately 2- to 3-fold. The HeFH can be diagnosed using well-established clinical criteria that include LDL-C levels, a family history of hypercholesterolemia and premature CHD.<sup>
<xref ref-type="bibr" rid="bibr8-0003319712465171">8</xref>
<xref ref-type="bibr" rid="bibr9-0003319712465171"/>–<xref ref-type="bibr" rid="bibr10-0003319712465171">10</xref>
</sup> In addition, molecular genetic testing can provide certainty of diagnosis in some cases where confounding factors such as borderline cholesterol levels and inconclusive family histories have resulted in a diagnostic dilemma.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712465171">11</xref>
</sup> The HoFH is a rare disorder; it presents with a marked increase in LDL-C, tendon and tuberous xanthomas, and xanthelasmata early in life. Untreated children are unlikely to survive beyond young adulthood due to the high risk of early coronary events, sudden death, or myocardial infarction that may occur as early as in 1 to 2 years of age. Our index patient had features suggestive of both clinical atherosclerosis with positive stress test and subclinical atherosclerosis with a marked increase in cIMT, especially when we consider the age and gender of the patient.</p>
<p>The diagnosis and the management of FH have been emphasized by both the National Institute for Health and Clinical Excellence (NICE) guidelines and the National Lipid Association (NLA) expert panel on FH.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712465171">12</xref>,<xref ref-type="bibr" rid="bibr13-0003319712465171">13</xref>
</sup> The NLA recommends, along with physical activity, a healthy diet and weight control, and statins as the first line of treatment for HeFH children.<sup>
<xref ref-type="bibr" rid="bibr13-0003319712465171">13</xref>
</sup> Statins can be started at an early age of 8 years and older and have been shown to be safe and effective by medium-term clinical trials. In FH, the treatment goal should be for LDL-C reduction of ≥50% or LDL-C &lt;132 mg/dL (3.43 mmol/L), but for those with additional risk factors for CHD, a lower LDL-C should be aimed for. In children with HoFH, statins might need to be initiated at an earlier age. Statins have been shown to improve survival rates and reduce cardiovascular events in patients with FH.<sup>
<xref ref-type="bibr" rid="bibr14-0003319712465171">14</xref>,<xref ref-type="bibr" rid="bibr15-0003319712465171">15</xref>
</sup> Although HoFH does not show much response to statins due to the absence of functional LDL receptors, statins help reduce the production of very dense lipoprotein cholesterol (VLDL) by the liver and therefore help in the reduction of the LDL-C. Studies have shown that ezetimibe is effective in reducing the LDL-C in HoFH either alone or in combination with statins<sup>
<xref ref-type="bibr" rid="bibr16-0003319712465171">16</xref>
<xref ref-type="bibr" rid="bibr17-0003319712465171"/>
<xref ref-type="bibr" rid="bibr18-0003319712465171"/>
<xref ref-type="bibr" rid="bibr19-0003319712465171"/>
<xref ref-type="bibr" rid="bibr20-0003319712465171"/>
<xref ref-type="bibr" rid="bibr21-0003319712465171"/>
<xref ref-type="bibr" rid="bibr22-0003319712465171"/>–<xref ref-type="bibr" rid="bibr23-0003319712465171">23</xref>
</sup> or LDL apheresis.<sup>
<xref ref-type="bibr" rid="bibr24-0003319712465171">24</xref>
</sup> In children, small studies of short- and medium-term duration have shown in general that ezetimibe is effective and well tolerated, with similar results to those observed in adults with FH<sup>
<xref ref-type="bibr" rid="bibr25-0003319712465171">25</xref>
<xref ref-type="bibr" rid="bibr26-0003319712465171"/>
<xref ref-type="bibr" rid="bibr27-0003319712465171"/>–<xref ref-type="bibr" rid="bibr28-0003319712465171">28</xref>
</sup>; nevertheless, long-term data are needed for safety and cardiovascular outcomes.</p>
<p>Treatment of children with HoFH is a challenge and, in most cases, the response to statins treatment requires LDL apheresis that has been shown to be effective in reducing the LDL-C and improving survival rates.<sup>
<xref ref-type="bibr" rid="bibr29-0003319712465171">29</xref>
<xref ref-type="bibr" rid="bibr30-0003319712465171"/>–<xref ref-type="bibr" rid="bibr31-0003319712465171">31</xref>
</sup> Additional modalities, such as liver transplantation and gene therapy, may be beneficial in the management of patients with FH. Further research is being conducted to establish novel and new targets for the treatment of FH such as APOB antisense, microsomal triglyceride transfer protein (MTP) inhibitors, and PCSK9 inhibitors.<sup>
<xref ref-type="bibr" rid="bibr32-0003319712465171">32</xref>
</sup> Lomitapide is an oral inhibitor of MTP and has been shown in phase 2 studies to reduce the LDL-C by 50% to 60% in HoFH. However, the drug has also been associated with some changes in the liver fat content.<sup>
<xref ref-type="bibr" rid="bibr33-0003319712465171">33</xref>
</sup> The REGN727 is a monoclonal antibody directed against the PCSK9 that inactivates hepatic LDL receptors, thereby reducing the clearance of LDL-C from the circulation. In a phase 2 study, the average LDL reduction with this drug was 102 mg/dL (2.64 mmol/L) from the baseline. Both drugs are currently undergoing phase 3 trials.<sup>
<xref ref-type="bibr" rid="bibr34-0003319712465171">34</xref>,<xref ref-type="bibr" rid="bibr35-0003319712465171">35</xref>
</sup>
</p>
<p>The FH is a genetically heterogeneous disorder. Mutations that co-segregate with the disease have been found in at least 3 genes; an <italic>LDLR</italic> accounts for 79%, with over 1000 mutations spread throughout gene. The <italic>APOB</italic> gene mutation accounts for 5.5%, with 9 mutations identified, and <italic>PCSK9 </italic>accounts for 1.5%, with 6 mutations identified.</p>
<p>There is a moderate degree of overlap between patients with and without FH if cholesterol levels are used to diagnose FH.<sup>
<xref ref-type="bibr" rid="bibr36-0003319712465171">36</xref>
</sup> In addition, a family history of CHD may not be conclusive in the presence of early treatment and well-controlled cholesterol with statins in affected family members. Therefore, the use of molecular genetic testing with cascade screening has major value in predicting family members with FH.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712465171">11</xref>
</sup> Cascade screening has been shown to be cost effective in detecting patients with HeFH.<sup>
<xref ref-type="bibr" rid="bibr37-0003319712465171">37</xref><xref ref-type="bibr" rid="bibr38-0003319712465171"/><xref ref-type="bibr" rid="bibr39-0003319712465171"/>–<xref ref-type="bibr" rid="bibr40-0003319712465171">40</xref>
</sup> This involves screening the family of the index patient using clinical diagnostic criteria and DNA analysis for the <italic>LDLR</italic>, <italic>APOB</italic>, and <italic>PCSK9</italic> genetic mutations. The prevalence of FH in Oman is not well established. In our institution, we have started a pilot study utilizing cascade screening to characterize the molecular genetics of FH.</p>
</sec>
<sec id="section4-0003319712465171">
<title>Conclusions</title>
<p>The FH is an autosomal dominant disorder that results in high levels of LDL-C and premature atherosclerosis if undiagnosed and not treated early. The diagnosis is based on elevated plasma LDL-C, a family history of hypercholesterolemia or premature coronary artery disease and molecular diagnosis. The treatment consists of lipid-lowering treatment and LDL apheresis in cases of HoFH. Early detection and treatment of FH using clinical criteria and cascade screening is the best approach to prevent cardiovascular disease.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank the apheresis nurses for their support in setting up the LDL apheresis service.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712465171">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712465171">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712465171">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Hobbs</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>MS.</given-names>
</name>
</person-group> <article-title>Familial hypercholesterolemia</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Scriver</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D</given-names>
</name>
</person-group>, eds. <source>The Metabolic and Molecular Bases of Inherited Disease</source>. <edition>8th ed</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>2001</year>; <fpage>2863</fpage>–<lpage>2913</lpage>. </citation>
</ref>
<ref id="bibr2-0003319712465171">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leitersdorf</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vander-Westhuyzen</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Coetzee</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Hobbs</surname>
<given-names>HH</given-names>
</name>
</person-group>. <article-title>Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners</article-title>. <source>J Clin Invest</source>. <year>1989</year>;<volume>84</volume>(<issue>3</issue>):<fpage>954</fpage>–<lpage>961</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712465171">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moorjani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gagnè</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Homozygous familial hypercholesterolemia among French Canadians in Quèbec Province</article-title>. <source>Arteriosclerosis</source>. <year>1989</year>;<volume>9</volume>(<issue>2</issue>):<fpage>211</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712465171">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marks</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thorogood</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Neil</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Humphries</surname>
<given-names>SE</given-names>
</name>
</person-group>. <article-title>A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia</article-title>. <source>Atherosclerosis</source>. <year>2003</year>;<volume>168</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712465171">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Austin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hutter</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Zimmern</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Humphries</surname>
<given-names>SE</given-names>
</name>
</person-group>. <article-title>Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review</article-title>. <source>Am J Epidemiol</source>. <year>2004</year>;<volume>160</volume>(<issue>5</issue>):<fpage>407</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712465171">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Austin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hutter</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Zimmern</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Humphries</surname>
<given-names>SE</given-names>
</name>
</person-group>. <article-title>Familial hypercholesterolemia and coronary heart disease: a HuGE association review</article-title>. <source>Am J Epidemiol</source>. <year>2004</year>;<volume>160</volume>(<issue>5</issue>):<fpage>421</fpage>–<lpage>429</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712465171">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hegele</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease</article-title>. <source>CMAJ</source>. <year>2006</year>;<volume>174</volume>(<issue>8</issue>):<fpage>1124</fpage>–<lpage>1129</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712465171">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schumacher</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics</article-title>. <source>Am J Cardiol</source>. <year>1993</year>;<volume>72</volume>(<issue>2</issue>):<fpage>171</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712465171">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betteridge</surname>
<given-names>DJ</given-names>
</name>
</person-group> <collab collab-type="author">for the Simon Broome Register Group</collab>. <article-title>Risk of fatal coronary heart disease in familial hypercholesterolemia</article-title>. <source>BMJ</source>. <year>1991</year>;<volume>303</volume>(<issue>6807</issue>):<fpage>893</fpage>–<lpage>896</lpage>.</citation>
</ref>
<ref id="bibr10-0003319712465171">
<label>10</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Defesche</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Familial hypercholesterolemia</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Betteridge</surname>
<given-names>DJ</given-names>
</name>
</person-group>, ed. <source>Lipids and Vascular Disease</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>Martin Dunitz Ltd</publisher-name>; <year>2000</year>:<fpage>65</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712465171">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Aalst-Cohen</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Tanck</surname>
<given-names>MW</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnosing familial hypercholesterolaemia: the relevance of genetic testing</article-title>. <source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>(<issue>18</issue>):<fpage>2240</fpage>–<lpage>2246</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712465171">
<label>12</label>
<citation citation-type="web">
<collab collab-type="author">National Institute for Health and Clinical Excellence</collab>. <article-title>Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia</article-title>. <year>2008</year> <comment>(Clinical guidelines 71)</comment>
<ext-link ext-link-type="uri" xlink:href="www.nice.org.uk/CG71">www.nice.org.uk/CG71</ext-link>.</citation>
</ref>
<ref id="bibr13-0003319712465171">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberg</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Toth</surname>
<given-names>PP</given-names>
</name>
</person-group>. <article-title>Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia</article-title>. <source>J Clin Lipidol</source>. <year>2011</year>;<volume>5</volume>(<issue>3 suppl</issue>):<fpage>S1</fpage>–<lpage>S8</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712465171">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Betteridge</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study</article-title>. <source>Eur Heart J</source>. <year>2008</year>;<volume>29</volume>(<issue>21</issue>):<fpage>2625</fpage>–<lpage>2633</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712465171">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raal</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Pilcher</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Panz</surname>
<given-names>VR</given-names>
</name>
<etal/>
</person-group>. <article-title>Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>124</volume>(<issue>20</issue>):<fpage>2202</fpage>–<lpage>2207</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712465171">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gagne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gaudet</surname>
<given-names>D</given-names>
</name>
</person-group>; <collab collab-type="author">Ezetimibe Study Group</collab>. <article-title>Homozygous familial hyper- cholesterolemia: a novel therapy with ezetimibe</article-title>. <source>Atherosclerosis</source>. <year>2002</year>;<volume>3</volume>(<issue>2</issue>):<fpage>81</fpage>.</citation>
</ref>
<ref id="bibr17-0003319712465171">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gaudet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</name>
</person-group>, <collab collab-type="author">for the Ezetimibe Study Group</collab>. <article-title>Efficacy and safety of ezetimibe co administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>(<issue>21</issue>):<fpage>2469</fpage>–<lpage>2475</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712465171">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gaudet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Ezetimibe significantly reduces low-density lipoprotein cholesterol in homozygous familial hyper- cholesterolemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>29</volume>(<issue>9 suppl B</issue>):<fpage>135B</fpage>.</citation>
</ref>
<ref id="bibr19-0003319712465171">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gaudet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>for the Exetimibe Study Group. Ezetimibe significantly reduces the low-density lipoprotein cholesterol in homozygous familial hyper- cholesterolemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>39</volume>(<issue>suppl A</issue>):<fpage>227A</fpage>.</citation>
</ref>
<ref id="bibr20-0003319712465171">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>HHJ</given-names>
</name>
<name>
<surname>Tietge</surname>
<given-names>UJF</given-names>
</name>
<name>
<surname>Buettner</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous pW577R LDL-receptor gene mutation</article-title>. <source>Clin Transplant</source>. <year>2008</year>;<volume>22</volume>(<issue>2</issue>):<fpage>180</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr21-0003319712465171">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamato</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harada-Shiba</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy</article-title>. <source>Atherosclerosis</source>. <year>2006</year>;<volume>186</volume>(<issue>1</issue>):<fpage>126</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr22-0003319712465171">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kassner</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Steinhagen-Thiessen</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Intensified lipid lowering treatment with lipid-apheresis and atorvastatin coadministered with ezetimibe in two children with homozygous familial hypercholesterolemia</article-title>. <source>Atherosclerosis</source>. <year>2004</year>;<volume>5</volume>(<issue>suppl 1</issue>):<fpage>120</fpage>.</citation>
</ref>
<ref id="bibr23-0003319712465171">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolovou</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Dedoussis</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Anagnostopoulou</surname>
<given-names>KK</given-names>
</name>
<etal/>
</person-group>. <article-title>Management of a patient with a null low-density lipoprotein receptor mutation: a case report</article-title>. <source>Angiology</source>. <year>2006</year>;<volume>57</volume>(<issue>6</issue>):<fpage>729</fpage>–<lpage>732</lpage>.</citation>
</ref>
<ref id="bibr24-0003319712465171">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geiss</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hund-Wissner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Parhofer</surname>
<given-names>KG</given-names>
</name>
</person-group>. <article-title>Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins</article-title>. <source>Atherosclerosis</source>. <year>2005</year>;<volume>180</volume>(<issue>1</issue>):<fpage>107</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr25-0003319712465171">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ullah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>SA</given-names>
</name>
</person-group>. <article-title>Familial hypercholesterolemia in a paediatric patient</article-title>. <source>J Coll Physicians Surg Pak</source>. <year>2005</year>;<volume>15</volume>(<issue>9</issue>):<fpage>578</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr26-0003319712465171">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van der Graf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cuffie-Jackson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vissers</surname>
<given-names>MN</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy and safety of co administration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>(<issue>17</issue>):<fpage>1421</fpage>–<lpage>1429</lpage>.</citation>
</ref>
<ref id="bibr27-0003319712465171">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clauss</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wai</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Kavey</surname>
<given-names>REW</given-names>
</name>
<name>
<surname>Kuehl</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Ezetimibe treatment of pediatric patients with hypercholesterolemia</article-title>. <source>J Pediatr</source>. <year>2009</year>;<volume>154</volume>(<issue>6</issue>):<fpage>869</fpage>–<lpage>872</lpage>.</citation>
</ref>
<ref id="bibr28-0003319712465171">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeste</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chacon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Clemente</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Albisu</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gussinyé</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carrascosa</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Ezetimibe as monotherapy in the treatment of hyper- cholesterolemia in children and adolescents</article-title>. <source>J Pediatr Endocrinol Metab</source>. <year>2009</year>;<volume>22</volume>(<issue>6</issue>):<fpage>487</fpage>–<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr29-0003319712465171">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sekiguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kano</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolaemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS)</article-title>. <source>Atherosclerosis</source>. <year>1999</year>;<volume>144</volume>(<issue>2</issue>):<fpage>409</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr30-0003319712465171">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatami</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolaemia: a multicenter study. The LARS Investigators</article-title>. <source>Atherosclerosis</source>. <year>1992</year>;<volume>95</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr31-0003319712465171">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Breslow</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Improved survival of patient 5 with homozygous familial hypercholesterolaemia treated by plasma exchange</article-title>. <source>Br Med J (Clin Res Ed)</source>. <year>1985</year>;<volume>291</volume>(<issue>6510</issue>):<fpage>1671</fpage>–<lpage>1673</lpage>.</citation>
</ref>
<ref id="bibr32-0003319712465171">
<label>32</label>
<citation citation-type="book">
<collab collab-type="author">Aegerion Pharmaceuticals</collab>. <article-title>Aegerion Pharmaceuticals announces phase III 56-week data in HoFH patients taking investigational lomitapide is consistent with 26-week data [press release]</article-title>. <issue>May 31</issue>, <year>2011</year>.</citation>
</ref>
<ref id="bibr33-0003319712465171">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Gipe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bergeron</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>6736</volume>(<issue>12</issue>):<fpage>60771</fpage>–<lpage>60775</lpage>.</citation>
</ref>
<ref id="bibr34-0003319712465171">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sijbrands</surname>
<given-names>EJG</given-names>
</name>
</person-group>. <article-title>Inhibition of PCSK9 in familial hypercholesterolaemia</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>6736</volume>(<issue>12</issue>):<fpage>60814</fpage>–<lpage>60819</lpage>.</citation>
</ref>
<ref id="bibr35-0003319712465171">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Florentin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liberopoulos</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>Emerging options in the treatment of dyslipidemias: a bright future?</article-title> <source>Expert Opin Emerg Drugs</source>. <year>2011</year>;<volume>16</volume>(<issue>2</issue>):<fpage>247</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr36-0003319712465171">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopkins</surname>
<given-names>PN</given-names>
</name>
</person-group>. <article-title>Defining the challenges of familial hypercholesterolemia screening: introduction</article-title>. <source>J Clin Lipidol</source>. <year>2010</year>;<volume>4</volume>(<issue>5</issue>):<fpage>342</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr37-0003319712465171">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umans-Eckenhausen</surname>
<given-names>MAW</given-names>
</name>
<name>
<surname>Defesche</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Sijbrands</surname>
<given-names>EGJ</given-names>
</name>
<name>
<surname>Scheerder</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Review of the first 5 years of screening for familial hypercholesterolemia in the Netherlands</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>357</volume>(<issue>9251</issue>):<fpage>165</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr38-0003319712465171">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Defesche</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lansberg</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Umans-Eckenhausen</surname>
<given-names>MAW</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Advanced method for the identification of patients with inherited hypercholesterolemia</article-title>. <source>Semin Vasc Med</source>. <year>2004</year>;<volume>4</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr39-0003319712465171">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umans-Eckenhausen</surname>
<given-names>MAW</given-names>
</name>
<name>
<surname>Defesche</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Van Dam</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Long term compliance to lipid lowering medication after genetic screening for familial hypercholesterolemia</article-title>. <source>Arch Intern Med</source>. <year>2003</year>;<volume>163</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr40-0003319712465171">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wonderling</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Umans-Eckenhausen</surname>
<given-names>MAW</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Defesche</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Thorogood</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>A cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands</article-title>. <source>Semin Vasc Med</source>. <year>2004</year>;<volume>4</volume>(<issue>1</issue>):<fpage>97</fpage>–<lpage>104</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>